Search Result

Results for "

MEK1/2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	MEK (35) Akt (8) AP-1 (1) Apoptosis (16) Autophagy (6) Beta-secretase (2) c-Met/HGFR (1) Calcium Channel (1) Caspase (2) CDK (1) Cholinesterase (ChE) (2) COX (2) DNA/RNA Synthesis (1) Drug Derivative (1) E3 Ligase Ligand-Linker Conjugates (2) ERK (7) FLT3 (1) GLP Receptor (3) Glutathione S-transferase (1) Isotope-Labeled Compounds (3) JAK (1) JNK (1) Keap1-Nrf2 (1) Ligands for Target Protein for PROTAC (2) MDM-2/p53 (1) Mitochondrial Metabolism (1) MMP (3) NF-κB (1) NO Synthase (1) p38 MAPK (3) PARP (1) PD-1/PD-L1 (1) PDGFR (1) PDK-1 (1) PERK (2) PI3K (2) PKC (1) PROTACs (2) Raf (2) Ras (1) Reactive Oxygen Species (ROS) (5) Reference Standards (5) SOD (1) Src (1) STAT (1) Topoisomerase (1) VEGFR (2) β-catenin (1)
By Research Areas:	Cancer (37) Cardiovascular Disease (5) Inflammation/Immunology (13) Metabolic Disease (9) Neurological Disease (11)

By Targets:

MEK (35)

Akt (8)

AP-1 (1)

Apoptosis (16)

Autophagy (6)

Beta-secretase (2)

c-Met/HGFR (1)

Calcium Channel (1)

Caspase (2)

CDK (1)

Cholinesterase (ChE) (2)

COX (2)

DNA/RNA Synthesis (1)

Drug Derivative (1)

E3 Ligase Ligand-Linker Conjugates (2)

ERK (7)

FLT3 (1)

GLP Receptor (3)

Glutathione S-transferase (1)

Isotope-Labeled Compounds (3)

JAK (1)

JNK (1)

Keap1-Nrf2 (1)

Ligands for Target Protein for PROTAC (2)

MDM-2/p53 (1)

Mitochondrial Metabolism (1)

MMP (3)

NF-κB (1)

NO Synthase (1)

p38 MAPK (3)

PARP (1)

PD-1/PD-L1 (1)

PDGFR (1)

PDK-1 (1)

PERK (2)

PI3K (2)

PKC (1)

PROTACs (2)

Raf (2)

Ras (1)

Reactive Oxygen Species (ROS) (5)

Reference Standards (5)

SOD (1)

Src (1)

STAT (1)

Topoisomerase (1)

VEGFR (2)

β-catenin (1)

By Research Areas:

Cancer (37)

Cardiovascular Disease (5)

Inflammation/Immunology (13)

Metabolic Disease (9)

Neurological Disease (11)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Targets Recommended: MEK ASK1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50706

Selumetinib Maximum Cited Publications 90 Publications Verification AZD6244; ARRY-142886	MEK Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Selumetinib (AZD6244) is selective, non-ATP-competitive oral *MEK1/2* inhibitor, with an IC₅₀ of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation. Selumetinib can penetrate the blood brain barrier (BBB) ^[1] .

HY-15202

Binimetinib 45+ Cited Publications MEK162; ARRY-162; ARRY-438162	MEK Autophagy	Cancer
Binimetinib (MEK162) is an oral and selective *MEK1/2* inhibitor. Binimetinib (MEK162) inhibits *MEK* with an IC₅₀ of 12 nM.

HY-132844

Tunlametinib HL-085	MEK	Cancer
Tunlametinib is a highly selective, orally active MEK1/2 inhibitor (IC₅₀=1.9 nM, MEK1). Tunlametinib blocks the RAS-RAF-MEK-ERK signaling pathway, arrests tumor cell cycle and promotes apoptosis. Tunlametinib potently inhibits the proliferation of RAS/RAF mutant cancer cells (such as BRAF V600E, KRAS G12C mutant cells). Tunlametinib shows synergistic anti-tumor effects with BRAF/KRASG12C/SHP2 inhibitors, Docetaxel (HY-B0011). Tunlametinib can be used to study targeted therapy for RAS/RAF mutation-driven malignancies (such as melanoma, colorectal cancer, and non-small cell lung cancer) ^[1] .

HY-12042

Pimasertib 5+ Cited Publications AS703026; MSC1936369B	MEK	Cancer
Pimasertib (AS703026) is a highly selective, ATP non-competitive allosteric orally available *MEK1/2* inhibitor ^[1] .

HY-P0119

Lixisenatide 2 Publications Verification	GLP Receptor Akt MEK Apoptosis Reactive Oxygen Species (ROS) MMP	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the *Akt-MEK1/2* signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis ^[1] .

HY-13425

Deguelin Maximum Cited Publications 15 Publications Verification (-)-Deguelin; (-)-cis-Deguelin	Akt Autophagy Apoptosis	Cancer
Deguelin, a naturally occurring rotenoid, acts as a chemopreventive agent by blocking multiple pathways like PI3K-Akt, IKK-NF-κB, and MAPK-mTOR-survivin-mediated apoptosis. Deguelin binding to Hsp90 leads to a decreased expression of numerous oncogenic proteins, including MEK1/2, Akt, HIF1α, COX-2, and NF-κB.

HY-50706A

Selumetinib sulfate Maximum Cited Publications 90 Publications Verification AZD6244 sulfate; ARRY-142886 sulfate	MEK Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Selumetinib (AZD6244) sulfate is selective, non-ATP-competitive oral *MEK1/2* inhibitor, with an IC₅₀ of 14 nM for MEK1. Selumetinib (AZD6244) sulfate inhibits ERK1/2 phosphorylation. Selumetinib sulfate can penetrate the blood brain barrier (BBB) ^[1] .

HY-N0226A

Epiberberine chloride 4 Publications Verification	Cholinesterase (ChE) Beta-secretase Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease
Epiberberine chloride is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive *BACE1* inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine chloride has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and may protect against Alzheimer disease ^[1]. Epiberberine chloride inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberine has the potential effect in the research of diabetic disease .

HY-N0226

Epiberberine	Cholinesterase (ChE) Beta-secretase	Neurological Disease Metabolic Disease
Epiberberine is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive *BACE1* inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and can be used for the research of Alzheimer disease ^[1]. Epiberberine inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberinecan be used for the research of diabetic disease .

HY-B0023

Azelnidipine 3 Publications Verification CS 905	Calcium Channel MEK	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Azelnidipine (CS 905) is a dihydropyridine calcium channel blocker that is effective orally. Azelnidipine inhibits the intracellular calcium ion flow and lower blood pressure by selectively blocking L-type calcium channel on the membrane of vascular smooth muscle. Azelnidipine inhibits esophageal squamous cell carcinoma proliferation by targeting *MEK1/2*. Azelnidipine also has anti-inflammatory, antioxidant and neuroprotective effects ^[1] .

HY-12062

PD318088 1 Publications Verification	MEK	Cancer
PD318088 is a potent, allosteric and non-ATP competitive *MEK1/2* inhibitor, an analog of PD184352 (HY-50295). PD318088 binds simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site. PD318088 can be used for cancer research ^[1].

HY-100627

APS-2-79	MEK	Cancer
APS-2-79 is a KSR-dependent *MEK* antagonist. APS-2-79 inhibits ATP ^biotin binding to KSR2 within the KSR2-MEK1 complexe with an IC₅₀ of 120 nM. APS-2-79 makes the stabilization of the KSR inactive state antagonizes oncogenic Ras-MAPK signaling .

HY-145702

MAP855	MEK ERK	Cancer
MAP855 is a highly potent, selective, ATP-competitive and orally active *MEK1/2* kinase inhibitor (MEK1 ERK2 cascade IC₅₀=3 nM, pERK EC₅₀=5 nM). MAP855 shows equipotent inhibition of wild-type and mutant MEK1/2 ^[1].

HY-N12445

Quercetin-3'-O-glucoside 1 Publications Verification	Topoisomerase Caspase Apoptosis SOD	Metabolic Disease Inflammation/Immunology Cancer
Quercetin-3'-O-glucoside is an orally active flavonoid glycoside. Quercetin-3'-O-glucoside reduces liver glucose-6-phosphatase activity, alters serum insulin and glucose levels, and regulates the activities of antioxidant enzymes in the liver and kidney. Quercetin-3'-O-glucoside inhibits DNA topoisomerase II, induces S-phase cell cycle arrest and caspase-3-mediated apoptosis in hepatocellular carcinoma cells. Quercetin-3'-O-glucoside selectively inhibits EGFR-mediated signaling pathways targeting AKT, ERK1/2, FAK and MEK1/2. Quercetin-3'-O-glucoside inhibits growth factor-induced migration and invasion in pancreatic cancer cells. Quercetin-3'-O-glucoside exerts free radical scavenging effects. Quercetin-3'-O-glucoside is applicable to research related to pancreatic cancer, diabetes, hepatocellular carcinoma and malignant tumors ^[1] .

HY-N0909

Notoginsenoside R2 1 Publications Verification 20(S)-Notoginsenoside R2; Ginsenoside Ng-R2	Apoptosis MEK ERK Reactive Oxygen Species (ROS) Caspase COX β-catenin Src MDM-2/p53 JAK STAT	Neurological Disease Metabolic Disease Inflammation/Immunology
Notoginsenoside R2 (20(S)-Notoginsenoside R2; Ginsenoside Ng-R2) is an orally active notoginsenoside . Notoginsenoside R2 activates P90RSK and Nrf2 via the *MEK1/2-ERK1/2* pathway to inhibit 6-OHDA-induced apoptotic damage in nerve cells. Notoginsenoside R2 upregulates SOX8/β-catenin by reducing miR-27a, thereby suppressing Aβ_25-35-induced neuronal apoptosis and inflammatory responses . Notoginsenoside R2 alleviates lipid accumulation and mitochondrial dysfunction in diabetic nephropathy by inhibiting c-Src. Notoginsenoside R2 alleviates hepatic fibrosis by inducing hepatic stellate cell senescence and inhibiting the inflammatory microenvironment via JAK/STAT3 suppression . Notoginsenoside R2 can be used in research related to Parkinson's disease, Alzheimer's disease, diabetic nephropathy and hepatic fibrosis ^[1] .

HY-153863

MS934	PROTACs MEK Raf	Cancer
MS934 is a novel improved VHL-recruiting *MEK 1/2* PROTAC degrader. MS934 also degrades CRAF. MS934 can be used for the research of variety of human cancers, such as melanoma, nonsmall cell lung cancer (NSCLC), colorectal cancer, primary brain tumors, and hepatocellular carcinoma (Pink: Target protein ligand (HY-168288); Black: linker (HY-168289); Blue: E3 ligase ligand (HY-112078)) ^[1] .

HY-P0119A

Lixisenatide acetate 2 Publications Verification	GLP Receptor Akt MEK Reactive Oxygen Species (ROS) Apoptosis MMP	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide acetate inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the *Akt-MEK1/2* signaling pathway. Lixisenatide acetate can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide acetate can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis ^[1] .

HY-131295

PD0325901-O-C2-dioxolane 2 Publications Verification	MEK Ligands for Target Protein for PROTAC	Cancer
PD0325901-O-C2-dioxolane has main portion of *MEK* inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader ^[1].

HY-115674

ML175	Glutathione S-transferase Akt MEK	Neurological Disease Inflammation/Immunology
ML175 is a specific glutathione transferase Omega 1-1 (GSTO1-1) inhibitor. ML175 can significantly activate Akt and *MEK1/2* kinases. ML175 can be used in the research of diseases such as Parkinson's disease ^[1].

HY-113592

ERK-IN-4 1 Publications Verification	ERK	Cancer
ERK-IN-4 is an ERK inhibitor binds preferentially to ERK2 with a K_d of 5 μM. ERK-IN-4 specificity inhibits ERK Rsk-1 and Elk-1 phosphorylation. ERK-IN-4 has little effect on ERK protein phosphorylation by its upstream activator MEK1/2 ^[1].

HY-170982

MS910	MEK PROTACs	Cancer
MS910 is an efficient and selective MEK1/2 PROTAC degrader. MS910 exhibits effective MEK1/2 degradation ability and anti proliferative activity in various cancer cells, such as HT-29 (MEK1 DC₅₀ = 118 nM, MEK2 DC₅₀ = 55 nM) and SK-MEL-28 (MEK1 DC₅₀ = 94 nM, MEK2 DC₅₀ = 38 nM) cells. MS910 is commonly used in cancer research. (Pink: MEK1/2 Ligand (HY-10254); Blue: CRBN Ligand (HY-W087383); Black: Linker (HY-W022240)) ^[1]

HY-145701

MEK1/2-IN-2	MEK	Cancer
MEK1/2-IN-2 is a potent ATP-competitive *MEK1/2* inhibitor and shows equipotent inhibition of WT MEK1/2 and a panel of MEK1/2 mutant cell lines ^[1].

HY-111033

RO5068760	MEK ERK Apoptosis p38 MAPK CDK PARP	Inflammation/Immunology Cancer
RO5068760 is a potent, orally active and selective non-ATP-competitive *MEK1/2* inhibitor with an IC₅₀ of 0.025 μM for MEK1. RO5068760 significantly inhibits MAPK pathway activity, thereby inducing G1 cell cycle arrest and apoptosis to inhibit cancer cell growth. RO5068760 exhibits significant efficacy in a broad spectrum of tumors with aberrant MAPK pathway activation. RO5068760 can be used for melanoma, colorectal cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer research ^[1].

HY-13425R

Deguelin (Standard) (-)-Deguelin (Standard); (-)-cis-Deguelin (Standard)	Akt Autophagy Apoptosis Reference Standards	Cancer
Deguelin (Standard) is the analytical standard of Deguelin. This product is intended for research and analytical applications. Deguelin, a naturally occurring rotenoid, acts as a chemopreventive agent by blocking multiple pathways like PI3K-Akt, IKK-NF-κB, and MAPK-mTOR-survivin-mediated apoptosis. Deguelin binding to Hsp90 leads to a decreased expression of numerous oncogenic proteins, including MEK1/2, Akt, HIF1α, COX-2, and NF-κB.

HY-100627A

APS-2-79 hydrochloride	MEK	Cancer
APS-2-79 hydrochloride is a KSR-dependent *MEK* antagonist. APS-2-79 inhibits ATP ^biotin binding to KSR2 within the KSR2-MEK1 complexe with an IC₅₀ of 120 nM. APS-2-79 makes the stabilization of the KSR inactive state antagonizes oncogenic Ras-MAPK signaling .

HY-50706R

Selumetinib (Standard) AZD6244 (Standard); ARRY-142886 (Standard)	MEK Apoptosis Reference Standards	Cancer
Selumetinib (Standard) is the analytical standard of Selumetinib. This product is intended for research and analytical applications. Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.

HY-15202R

Binimetinib (Standard) MEK162 (Standard); ARRY-162 (Standard); ARRY-438162 (Standard)	Reference Standards MEK Autophagy	Cancer
Binimetinib (Standard) is the analytical standard of Binimetinib. This product is intended for research and analytical applications. Binimetinib (MEK162) is an oral and selective *MEK1/2* inhibitor. Binimetinib (MEK162) inhibits *MEK* with an IC₅₀ of 12 nM.

HY-12482

X-370	PI3K Apoptosis PDK-1 MEK Akt ERK	Cancer
X-370 is a PI3Kδ inhibitor (IC₅₀ = 7 nM). X-370 inhibits the survival of leukemia cells, inducing G1 arrest and apoptosis. X-370 blocks *PDK1* binding and phosphorylation of *MEK1/2, eliminating Akt* and *Erk1/2* signaling. X-370 can be used in research on B-cell acute lymphoblastic leukemia (B-ALL) ^[1].

HY-10338A

Foretinib phosphate	c-Met/HGFR VEGFR	Cancer
Foretinib phosphate is an orally bioavailable small molecule with potential anti-tumor activity. Foretinib phosphate can selectively inhibit hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), thereby potentially inhibiting tumor angiogenesis, tumor cell proliferation and metastasis. Foretinib phosphate shows different anti-cancer activity from cabozantinib in lung cancer cells and has stronger inhibitory effects on targets such as MEK1/2, FER and AURKB ^[1].

HY-123586

L-783277	MEK VEGFR FLT3 PDGFR	Cancer
L-783277 (Compound 4) is a *MEK* inhibitor (IC₅₀ = 4 nM). L-783277 has potent inhibitory activity against a variety of kinases, including VEGFR2/3, *FLT1/3/4, MEK1/2, KDR, and PDGFRα, but has low selectivity for the kinase community. L-783277 inhibits viability (IC₅₀* = 22 mM) and cell proliferation (IC₅₀ = 21 mM) of H295R cells. L-783277 could be used in research on cancers such as adrenocortical carcinoma ^[1] .

HY-12042A

Pimasertib hydrochloride AS703026 hydrochloride; MSC1936369B hydrochloride	MEK	Cancer
Pimasertib hydrochloride is a highly selective, ATP non-competitive allosteric orally available *MEK1/2* inhibitor ^[1] .

HY-50706AR

Selumetinib sulfate (Standard) AZD6244 sulfate (Standard); ARRY-142886 sulfate (Standard)	MEK Apoptosis Reference Standards	Cancer
Selumetinib (sulfate) (Standard) is the analytical standard of Selumetinib (sulfate). This product is intended for research and analytical applications. Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.

HY-12447

SMK-17	MEK Apoptosis	Cancer
SMK-17 is a selective, non-ATP-competitive *MEK1/MEK2* inhibitor with IC₅₀s of 62 nM and 56 nM, respectively. SMK-17 binds to the allosteric pocket of MEK1/2. SMK-17 induces apoptosis in tumor cell lines harboring β-catenin mutations ^[1].

HY-13303

RO 4927350	MEK	Cancer
RO 4927350 is a potent and selective non-ATP-competitive MEK1/2 inhibitor. RO 4927350 exhibits significant antitumor efficacy in a broad spectrum of tumor models ^[1].

HY-126048

JTP-70902	MEK	Cancer
JTP-70902, a p15 ^INK4b-inductive compound, is a *MEK1/2* inhibitor. JTP-70902 exhibits potent antitumor effect ^[1].

HY-15202S3

Binimetinib-d4 MEK162-d₄; ARRY-162-d₄; ARRY-438162-d₄	Isotope-Labeled Compounds Autophagy MEK	Cancer
Binimetinib-d₄ (MEK162-d₄) is deuterium labeled Binimetinib. Binimetinib (MEK162) is an oral and selective *MEK1/2* inhibitor. Binimetinib (MEK162) inhibits *MEK* with an IC₅₀ of 12 nM.

HY-15202S1

Binimetinib-d3 MEK162-d₃; ARRY-162-d₃; ARRY-438162-d₃	Isotope-Labeled Compounds MEK Autophagy	Cancer
Binimetinib-d₃ (MEK162-d₃) is deuterium labeled Binimetinib. Binimetinib (MEK162) is an oral and selective *MEK1/2* inhibitor. Binimetinib (MEK162) inhibits *MEK* with an IC₅₀ of 12 nM ^[1].

HY-130642

(S,R,S)-AHPC-Me-C10-Br	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-Me-C10-Br is a synthesized E3 ligase ligand-linker conjugate. (S,R,S)-AHPC-Me-C10-Br incorporates a VHL E3 ligase linker and MS432 based on the MEK1/2 inhibitor PD0325901 ^[1].

HY-120485

Raxofelast IRFI-016	p38 MAPK ERK PKC	Cardiovascular Disease
Raxofelast (IRFI-016) is an antioxidant agent in various models of ischemia-reperfusion injury. Raxofelast has antiproliferative activity in H₂O₂-stimulated rat aortic smooth muscle cells. Raxofelast attenuates the activation of mitogen-activating protein kinase (MAPK), ERK kinase 1, 2 (MEK1,2) and protein kinase C (PKC) without affecting Ras expression ^[1].

HY-168288

MEK ligand-2	MEK Ligands for Target Protein for PROTAC	Cancer
MEK ligand-2, a **MEK1 and MEK2** inhibitor, is a ligand for target protein for PROTAC of MS934 (HY-153863). MS934 is a VHL-recruiting MEK 1/2 PROTAC degrader ^[1].

HY-173153

BRAFV600E/JNK-IN-1	JNK PERK MEK NO Synthase	Inflammation/Immunology Cancer
BRAFV600E/JNK-IN-1 (Compound 14c) is an inhibitor of JNK1, JNK2, JNK3 and BRAFV600E, with IC₅₀ values of 0.51 μM, 0.53 μM, 1.02 μM and 0.009 μM, respectively. BRAFV600E/JNK-IN-1 can inhibit the phosphorylation of *MEK1/2* and *ERK1/2. In addition, BRAFV600E/JNK-IN-1 can inhibit tumor cell proliferation, NO release and PGE2* production, and has anti-tumor and anti-inflammatory activities ^[1].

HY-P0119S

Lixisenatide (Leu-13C6,15N) TFA	Isotope-Labeled Compounds GLP Receptor Akt MEK Apoptosis Reactive Oxygen Species (ROS) MMP	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the *Akt-MEK1/2* signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis ^[1] .

HY-180327

NEPP11	Drug Derivative Apoptosis Keap1-Nrf2 Raf MEK ERK	Neurological Disease Inflammation/Immunology
NEPP11 is a cyclopentenone prostaglandin analogue. NEPP11 can inhibit glutamate-induced HT22 cell death in mouse hippocampus and prevent manganese-induced apoptosis in PC12 cells. NEPP11 can activate Nrf2 and maintain *MEK1/2* and *ERK1/2* activity by inhibiting c-Raf downregulation. NEPP11 exerts a neuroprotective effect in a mouse model of focal cerebral ischemia caused by permanent middle cerebral artery occlusion ^[1].

HY-168290

(S,R,S)-AHPC-Me-12-((4-Bromobutyl)amino)dodecanamide	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-Me-12-((4-Bromobutyl)amino)dodecanamide incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-Me-12-((4-Bromobutyl)amino)dodecanamide can be used in the synthesis of PROTACs, such as MS934 (HY-153863). MS934 is a novel improved VHL-recruiting *MEK 1/2* PROTAC degrader ^[1].

HY-100627R

APS-2-79 (Standard)	MEK Reference Standards	Cancer
APS-2-79 (Standard) is the analytical standard of APS-2-79 (HY-100627). This product is intended for research and analytical applications. APS-2-79 is a KSR-dependent MEK antagonist. APS-2-79 inhibits ATPbiotin binding to KSR2 within the KSR2-MEK1 complexe with an IC50 of 120 nM. APS-2-79 makes the stabilization of the KSR inactive state antagonizes oncogenic Ras-MAPK signaling .

HY-N9980

Antcin K	PI3K Akt NF-κB p38 MAPK AP-1	Inflammation/Immunology
Antcin K is a selective inhibitor targeting the PI3K/Akt, NF-κB, *MEK1/2-ERK, p38* and *AP-1* pathways. Antcin K upregulates IL-10 expression, thereby inhibiting the production of pro-inflammatory factors, blocking monocyte adhesion, reducing tissue damage, and promoting myogenesis. Antcin K has significant anti-inflammatory, anti-damage and tissue protective activities. Antcin K is mainly used in the research of inflammation-related diseases such as periodontitis, rheumatoid arthritis, and skeletal muscle injury ^[1] .

HY-182899

DPAP	PERK Ras COX PD-1/PD-L1 Apoptosis DNA/RNA Synthesis Mitochondrial Metabolism	Cancer
DPAP is a *p-ERK1/2* inhibitor with an IC₅₀ of 7.85 μM against p-ERK1/2. DPAP inhibits the expression of *p-MEK1/2* and disrupts the Ras-ERK signaling pathway. DPAP inhibits the expression of COX-2 in nerve cells. DPAP damages DNA and mitochondria, induces Apoptosis via the mitochondrial pathway, and upregulates *PD-L1. DPAP inhibits melanoma metastasis and angiogenesis, and inactivates spinal microglia and astrocytes. DPAP exhibits anti-melanoma activity and can be combined with anti-PD-1* monoclonal antibodies to modify anti-tumor effects. DPAP is applicable for the research of melanoma ^[1].

Cat. No.	Product Name	Target	Research Area

HY-P0119

Lixisenatide 2 Publications Verification	GLP Receptor Akt MEK Apoptosis Reactive Oxygen Species (ROS) MMP	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the *Akt-MEK1/2* signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis ^[1] .

HY-P0119A

Lixisenatide acetate 2 Publications Verification	GLP Receptor Akt MEK Reactive Oxygen Species (ROS) Apoptosis MMP	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide acetate inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the *Akt-MEK1/2* signaling pathway. Lixisenatide acetate can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide acetate can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis ^[1] .

HY-P0119S

Lixisenatide (Leu-13C6,15N) TFA	Isotope-Labeled Compounds GLP Receptor Akt MEK Apoptosis Reactive Oxygen Species (ROS) MMP	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the *Akt-MEK1/2* signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis ^[1] .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-13425

Deguelin Maximum Cited Publications 15 Publications Verification (-)-Deguelin; (-)-cis-Deguelin	Flavonoids Classification of Application Fields Leguminosae Isoflavanones Derris trifoliata Lour. Plants Disease Research Fields Biological Pesticide Research Source Classification Cancer Agricultural Research	Akt Autophagy Apoptosis
Deguelin, a naturally occurring rotenoid, acts as a chemopreventive agent by blocking multiple pathways like PI3K-Akt, IKK-NF-κB, and MAPK-mTOR-survivin-mediated apoptosis. Deguelin binding to Hsp90 leads to a decreased expression of numerous oncogenic proteins, including MEK1/2, Akt, HIF1α, COX-2, and NF-κB.

HY-N0226A

Epiberberine chloride 4 Publications Verification	Alkaloids Neurological Disease Classification of Application Fields Coptis chinensis Franch. Ranunculaceae Metabolic Disease Plants Isoquinoline Alkaloids Disease Research Fields Source Classification	Cholinesterase (ChE) Beta-secretase Reactive Oxygen Species (ROS)
Epiberberine chloride is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive *BACE1* inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine chloride has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and may protect against Alzheimer disease ^[1]. Epiberberine chloride inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberine has the potential effect in the research of diabetic disease .

HY-N0226

Epiberberine	Alkaloids Structural Classification Coptis chinensis Franch. Ranunculaceae Plants Isoquinoline Alkaloids Source Classification	Cholinesterase (ChE) Beta-secretase
Epiberberine is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive *BACE1* inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and can be used for the research of Alzheimer disease ^[1]. Epiberberine inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberinecan be used for the research of diabetic disease .

HY-N12445

Quercetin-3'-O-glucoside 1 Publications Verification	Malvaceae Structural Classification Flavonols Flavonoids Abelmoschus manihot (Linn.) Medicus Plants Source Classification	Topoisomerase Caspase Apoptosis SOD
Quercetin-3'-O-glucoside is an orally active flavonoid glycoside. Quercetin-3'-O-glucoside reduces liver glucose-6-phosphatase activity, alters serum insulin and glucose levels, and regulates the activities of antioxidant enzymes in the liver and kidney. Quercetin-3'-O-glucoside inhibits DNA topoisomerase II, induces S-phase cell cycle arrest and caspase-3-mediated apoptosis in hepatocellular carcinoma cells. Quercetin-3'-O-glucoside selectively inhibits EGFR-mediated signaling pathways targeting AKT, ERK1/2, FAK and MEK1/2. Quercetin-3'-O-glucoside inhibits growth factor-induced migration and invasion in pancreatic cancer cells. Quercetin-3'-O-glucoside exerts free radical scavenging effects. Quercetin-3'-O-glucoside is applicable to research related to pancreatic cancer, diabetes, hepatocellular carcinoma and malignant tumors ^[1] .

HY-N0909

Notoginsenoside R2 1 Publications Verification 20(S)-Notoginsenoside R2; Ginsenoside Ng-R2	Triterpenes Structural Classification Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow Neurological Disease Classification of Application Fields Terpenoids Plants Disease Research Fields Araliaceae Source Classification	Apoptosis MEK ERK Reactive Oxygen Species (ROS) Caspase COX β-catenin Src MDM-2/p53 JAK STAT
Notoginsenoside R2 (20(S)-Notoginsenoside R2; Ginsenoside Ng-R2) is an orally active notoginsenoside . Notoginsenoside R2 activates P90RSK and Nrf2 via the *MEK1/2-ERK1/2* pathway to inhibit 6-OHDA-induced apoptotic damage in nerve cells. Notoginsenoside R2 upregulates SOX8/β-catenin by reducing miR-27a, thereby suppressing Aβ_25-35-induced neuronal apoptosis and inflammatory responses . Notoginsenoside R2 alleviates lipid accumulation and mitochondrial dysfunction in diabetic nephropathy by inhibiting c-Src. Notoginsenoside R2 alleviates hepatic fibrosis by inducing hepatic stellate cell senescence and inhibiting the inflammatory microenvironment via JAK/STAT3 suppression . Notoginsenoside R2 can be used in research related to Parkinson's disease, Alzheimer's disease, diabetic nephropathy and hepatic fibrosis ^[1] .

HY-13425R

Deguelin (Standard) (-)-Deguelin (Standard); (-)-cis-Deguelin (Standard)	Structural Classification Flavonoids Leguminosae Isoflavanones Derris trifoliata Lour. Plants Source Classification	Akt Autophagy Apoptosis Reference Standards
Deguelin (Standard) is the analytical standard of Deguelin. This product is intended for research and analytical applications. Deguelin, a naturally occurring rotenoid, acts as a chemopreventive agent by blocking multiple pathways like PI3K-Akt, IKK-NF-κB, and MAPK-mTOR-survivin-mediated apoptosis. Deguelin binding to Hsp90 leads to a decreased expression of numerous oncogenic proteins, including MEK1/2, Akt, HIF1α, COX-2, and NF-κB.

HY-N9980

Antcin K	Structural Classification Microorganisms Steroids Source Classification	PI3K Akt NF-κB p38 MAPK AP-1
Antcin K is a selective inhibitor targeting the PI3K/Akt, NF-κB, *MEK1/2-ERK, p38* and *AP-1* pathways. Antcin K upregulates IL-10 expression, thereby inhibiting the production of pro-inflammatory factors, blocking monocyte adhesion, reducing tissue damage, and promoting myogenesis. Antcin K has significant anti-inflammatory, anti-damage and tissue protective activities. Antcin K is mainly used in the research of inflammation-related diseases such as periodontitis, rheumatoid arthritis, and skeletal muscle injury ^[1] .

Cat. No.	Product Name	Chemical Structure

HY-15202S3

Binimetinib-d4
Binimetinib-d₄ (MEK162-d₄) is deuterium labeled Binimetinib. Binimetinib (MEK162) is an oral and selective *MEK1/2* inhibitor. Binimetinib (MEK162) inhibits *MEK* with an IC₅₀ of 12 nM.

HY-15202S1

Binimetinib-d3
Binimetinib-d₃ (MEK162-d₃) is deuterium labeled Binimetinib. Binimetinib (MEK162) is an oral and selective *MEK1/2* inhibitor. Binimetinib (MEK162) inhibits *MEK* with an IC₅₀ of 12 nM ^[1].

HY-P0119S

Lixisenatide (Leu-13C6,15N) TFA

Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis ^[1] .

Host:	Rabbit (4)
Reactivity:	Human (4) Rat (4) Mouse (4)
Application:	IHC-P (4) ICC/IF (4) IF-Tissue (1) IP (4) WB (4) ELISA (2)
Isotype:	IgG (3) IgG/Kappa (1)
Conjugation:	Non-conjugated (4)
Clonality:	Monoclonal (3) Recombinant (1)
Modification:	Phosphorylated (1) Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80218

	MEK1/2 Antibody (YA299) 1 Publications Verification	WB, ICC/IF, IHC-P, IP	Human, Mouse, Rat
	MEK1/2 Antibody (YA299) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MEK1/2.

HY-P86457

	MEK-1/2 Antibody (YA6149) MAP2K1; MEK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; MAP kinase kinase 1; MAPKK 1; MKK1; ERK activator kinase 1; MAPK/ERK kinase 1; MEK 1; MAP2K2; MEK2; MKK2; PRKMK2; Dual specificity mitogen-activated protein k	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	MEK-1/2 Antibody (YA6149) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MEK-1/2.

HY-P810552

	*Phospho-MEK1/2* (Ser218 + S222) Antibody (YA9821)** MAP2K1; MEK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; MAP kinase kinase 1; MAPKK 1; MKK1; ERK activator kinase 1; MAPK/ERK kinase 1; MEK 1	WB, ICC/IF, IF-Tissue, IHC-P, IP	Human, Mouse, Rat
	Phospho-MEK1/2 (Ser218 + S222) Antibody (YA9821) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-MEK1/2 (Ser218 + S222).

HY-P86143

	*Phospho-MEK1/2(Ser217/221) Antibody (YA5835)*	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Phospho-MEK1/2(Ser217/221) Antibody (YA5835) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-MEK1/2(Ser217/221).

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MEK1/2

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Natural
Products